Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
Mallinckrodt
US Department of Justice
Argus Health
McKinsey
Dow
Fuji
AstraZeneca

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,344,479

« Back to Dashboard

Which drugs does patent 6,344,479 protect, and when does it expire?

Patent 6,344,479 protects NEOPROFEN and is included in one NDA.

This patent has six patent family members in six countries.
Summary for Patent: 6,344,479
Title: Method of preventing retinopathy of prematurity in a neonate
Abstract:A method is disclosed of preventing retinopathy of prematurity in a prematurely born neonate susceptible to developing retinopathy of prematurity, which comprises the step of parenterally administering to said prematurely born neonate, a therapeutically effective amount of a water-soluble, pharmaceutically effective salt of ibuprofen as an active ingredient to promote retinal and choroidal blood flow autoregulation in said neonate.
Inventor(s): Van Overmeire; Bart (Antwerp, BE), Darko; Laszlo (Westport, CT)
Assignee: Farmacon-Il, LLC (Westport, CT)
Application Number:09/813,280
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,344,479

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Recordati Rare NEOPROFEN ibuprofen lysine INJECTABLE;INTRAVENOUS 021903-001 Apr 13, 2006 AP RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y Y CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,344,479

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 318136 ➤ Try a Free Trial
Canada 2377453 ➤ Try a Free Trial
Germany 60209269 ➤ Try a Free Trial
European Patent Office 1249234 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Cantor Fitzgerald
Fuji
Deloitte
Johnson and Johnson
Chinese Patent Office
Medtronic
Daiichi Sankyo
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.